Conversion of MIG6 peptide from the nonbinder to binder of lung cancer-related EGFR by phosphorylation and cyclization

References

• Ai X, Sun Y, Wang H, Lu S. 2014. A systematic profile of clinical inhibitors responsive to EGFR somatic amino acid mutations in lung cancer: implication for the molecular mechanism of drug resistance and sensitivity. Amino Acids. 46:1635–1648.
   PubMed Web of Science ®Google Scholar
• Bethune G, Bethune D, Ridgway N, Xu Z. 2010. Epidermal growth factor receptor (EGFR) in lung cancer: an overview and update. J Thorac Dis. 2:48–51.
   PubMedGoogle Scholar
• Case DA, Cheatham TE, Darden T, Gohlke H, Luo R, Merz KM, et al. 2005. The amber biomolecular simulation programs. J Comput Chem. 26:1668–1688.
   PubMed Web of Science ®Google Scholar
• Chan LY, Gunasekera S, Henriques ST, Worth NF, Le SJ, Clark RJ, et al. 2011. Engineering pro-angiogenic peptides using stable disulfide-rich cyclic scaffolds. Blood. 118:6709–6717.
   PubMed Web of Science ®Google Scholar
• Darden T, York D, Pedersen L. 1993. Particle mesh Ewald: an N.log(N) method for Ewald sums in large systems. Chem Phys. 98:10089–10092.
   Web of Science ®Google Scholar
• Duan Y, Wu C, Chowdhury S, Lee MC, Xiong G, Zhang W, et al. 2003. A point-charge force field for molecular mechanics simulations of proteins based on condensed-phase quantum mechanical calculations. J Comput Chem. 24:1999–2012.
   PubMed Web of Science ®Google Scholar
• Ferby I, Reschke M, Kudlacek O, Knyazev P, Pantè G, Amann K, et al. 2006. Mig6 is a negative regulator of EGF receptor-mediated skin morphogenesis and tumor formation. Nat Med. 12:568–573.
   PubMed Web of Science ®Google Scholar
• Hackel PO, Gishizky M, Ullrich A. 2001. Mig-6 is a negative regulator of the epidermal growth factor receptor signal. Biol Chem. 382:1649–1662.
   PubMed Web of Science ®Google Scholar
• Jorgensen WL, Chandrasekhar J, Madura JD, Impey RW, Klein ML. 1983. Comparison of simple potential functions for simulating liquid water. J Chem Phys. 79:926–935.
   Web of Science ®Google Scholar
• Killian BJ, Kravitz JY, Somani S, Dasgupta P, Pang YP, Gilson MK. 2009. Configurational entropy in protein-peptide binding: computational study of Tsg101 ubiquitin E2 variant domain with an HIV-derived PTAP nonapeptide. J Mol Biol. 389:315–335.
   PubMed Web of Science ®Google Scholar
• Kim TH, Yoo JY, Kim HI, Gilbert J, Ku BJ, Li J, et al. 2014. Mig-6 suppresses endometrial cancer associated with Pten deficiency and ERK activation. Cancer Res. 74:7371–7382.
   PubMed Web of Science ®Google Scholar
• Izumchenko E, Sidransky D. 2015. Understanding the MIG6-EGFR signaling axis in lung tumorigenesis. Cancer Discov. 5:472–474.
   PubMed Web of Science ®Google Scholar
• Li ZX, Qu LY, Wen H, Zhong HS, Xu K, Qiu XS, Wang EH. 2014. Mig-6 overcomes gefitinib resistance by inhibiting EGFR/ERK pathway in non-small cell lung cancer cell lines. Int J Clin Exp Pathol. 7:7304–7311.
   PubMed Web of Science ®Google Scholar
• London N, Movshovitz-Attias D, Schueler-Furman O. 2010. The structural basis of peptide-protein binding strategies. Structure. 18:188–199.
   PubMed Web of Science ®Google Scholar
• Maity TK, Venugopalan A, Linnoila I, Cultraro CM, Giannakou A, Nemati R, et al. 2015. Loss of MIG6 accelerates initiation and progression of mutant epidermal growth factor receptor-driven lung adenocarcinoma. Cancer Discov. 5:534–549.
   PubMed Web of Science ®Google Scholar
• Moonrin N, Songtawee N, Rattanabunyong S, Chunsrivirot S, Mokmak W, Tongsima S, Choowongkomon K. 2015. Understanding the molecular basis of EGFR kinase domain/MIG-6 peptide recognition complex using computational analyses. BMC Bioinformatics. 16:103.
   PubMed Web of Science ®Google Scholar
• Park E, Kim N, Ficarro SB, Zhang Y, Lee BI, Cho A, et al. 2015. Structure and mechanism of activity-based inhibition of the EGF receptor by Mig6. Nat Struct Mol Biol. 22:703–711.
   PubMed Web of Science ®Google Scholar
• Park D, Magis AT, Li R, Owonikoko TK, Sica GL, Sun SY, et al. 2013. Novel small-molecule inhibitors of Bcl-XL to treat lung cancer. Cancer Res. 73:5485–5496.
   PubMed Web of Science ®Google Scholar
• Ryckaert JP, Ciccotti G, Berendsen HJC. 1977. Numerical integration of the Cartesian equations of motion of a system with constraints: molecular dynamics of n-alkanes. J Comput Phys. 23:327–341.
   Web of Science ®Google Scholar
• Steinbrecher T, Latzer J, Case DA. 2012. Revised AMBER parameters for bioorganic phosphates. J Chem Theory Comput. 8:4405–4412.
   PubMed Web of Science ®Google Scholar
• Vriend G. 1990. WHAT IF: A molecular modeling and drug design program. J Mol Graph. 8:52–56.
   PubMed Web of Science ®Google Scholar
• Wendt MK, Williams WK, Pascuzzi PE, Balanis NG, Schiemann BJ, Carlin CR, Schiemann WP. 2015. The antitumorigenic function of EGFR in metastatic breast cancer is regulated by expression of Mig6. Neoplasia. 17:124–133.
   PubMed Web of Science ®Google Scholar
• Yu H, Zhou P, Deng M, Shang Z. 2014. Indirect readout in protein-peptide recognition: a different story from classical biomolecular recognition. J Chem Inf Model. 54:2022–2032.
   PubMed Web of Science ®Google Scholar
• Yu XD, Yang R, Leng CJ. 2016. Truncation, modification, and optimization of MIG6(segment 2) peptide to target lung cancer-related EGFR. Comput Biol Chem. 61:251–257.
   PubMed Web of Science ®Google Scholar
• Yang C, Zhang S, He P, Wang C, Huang J, Zhou P. 2015. Self-binding peptides: folding or binding? J Chem Inf Model. 55:329–342.
   PubMed Web of Science ®Google Scholar
• Yang C, Zhang S, Bai Z, Hou S, Wu D, Huang J, Zhou P. 2016. A two-step binding mechanism for the self-binding peptide recognition of target domains. Mol Biosyst. 12:1201–1213.
   PubMed Web of Science ®Google Scholar
• Zhang X, Gureasko J, Shen K, Cole PA, Kuriyan J. 2006. An allosteric mechanism for activation of the kinase domain of epidermal growth factor receptor. Cell. 125:1137–1149.
   PubMed Web of Science ®Google Scholar
• Zhang X, Pickin KA, Bose R, Jura N, Cole PA, Kuriyan J. 2007. Inhibition of the EGF receptor by binding of MIG6 to an activating kinase domain interface. Nature. 450:741–744.
   PubMed Web of Science ®Google Scholar
• Zhang YW, Staal B, Su Y, Swiatek P, Zhao P, Cao B, et al. 2007. Evidence that MIG-6 is a tumor-suppressor gene. Oncogene. 26:269–276.
   PubMed Web of Science ®Google Scholar